Novavax, Inc. (NVAX) belongs to Healthcare sector USA industry. The company’s Market capitalization is $3347.21 with the total Outstanding Shares of 469.45 million. On 14-05-2019 (Tuesday), shares were closed at $7.13 a share in the latest session and the stock value gain almost 23.78% since the beginning of this year. The company has managed to keep price to sales ratio of 116.97. The price to sales ratio is the ratio of the market value of equity to the sales. This ratio is internally not steady, since the market value of equity is divided by the total revenues of the firm.
Measure Investors’ Interest before Making Any Investment Decision (RVOL Analysis):
The stock exchanged hands with a volume of 6.25 million shares compared to its standard daily volume. The stock has relative volume of 6.66. Relative Volume (or RVOL) is a volume indicator, meaning it helps measure investor interest in a stock. RVOL compares a stock’s current volume to its prior volume over a specific period.
It’s expressed as a ratio. For example, if a stock has an RVOL of 5, it’s trading at 5-times its normal volume. Higher Relative Volume obviously indicates more traders are trading it.
Few Important Technical Indicators:
Novavax, Inc. (NVAX) stock is currently trading -76.15% away from its average-price of 200 days while it maintained a distance of -32.14% from its 50 Days Moving Average and -25.05% compared with the 20 Day Moving Average. The stock, as of last close, traded 24.65% away to its 52 week low and was at a distance of -86.18% from its 52 week high. Novavax, Inc. (NVAX)’s value Change from Open was at 22.30% with a Gap of 1.22%.
Is the Stock Volatile?
ATR value of company was 0.88. Relative Strength Index (RSI) was 35.41. The stock volatility for week was 19.23% while for month was 9.45%.
How Earnings Impact Valuation:
EPS growth estimate for this year is set at 28.00%.The earnings per share (EPS) formula is stated as earnings available to common shareholders divided by number of common stock shares outstanding. EPS is an indicator of company profit because the more earnings a company can generate per share, the more valuable each share is to investors.
What to Expect From Novavax, Inc. (NVAX) in Coming 5 Years?
EPS in next five years is expected to touch 0.00%. EPS growth in next year is estimated to reach 16.70%.
What Do Analysts Recommend?
Consensus rating is 2.10 by the analysts on the stock. A consensus suggestion for any specific stock observes rating from many analysts who analyze that stock. These suggestions provide a complete picture of the stock. Consensus rating based on a 1-5 numerical scale. If the consensus rating is one, it will indicate a strong sign for buy. If it shows Three, it will be a signal for hold. If the rating on the numerical scale is five, it will consider as a strong sell.